Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung group study.
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms MAPPING
- 07 Jun 2017 Biomarkers information updated
- 11 Jun 2015 Interim results published in the European Journal of Cancer.
- 03 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.